193 related articles for article (PubMed ID: 20209387)
21. Cucurbitacins - a promising target for cancer therapy.
Alghasham AA
Int J Health Sci (Qassim); 2013 Jan; 7(1):77-89. PubMed ID: 23559908
[TBL] [Abstract][Full Text] [Related]
22. Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends.
Tuli HS; Rath P; Chauhan A; Ranjan A; Ramniwas S; Sak K; Aggarwal D; Kumar M; Dhama K; Lee EHC; Yap KC; Capinpin SM; Kumar AP
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671442
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in the Application of Cucurbitacins as Anticancer Agents.
Zieniuk B; Pawełkowicz M
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887406
[TBL] [Abstract][Full Text] [Related]
24. Cucurbitacins attenuate microglial activation and protect from neuroinflammatory injury through Nrf2/ARE activation and STAT/NF-κB inhibition.
Park SY; Kim YH; Park G
Neurosci Lett; 2015 Nov; 609():129-36. PubMed ID: 26472707
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics.
Dai S; Wang C; Zhao X; Ma C; Fu K; Liu Y; Peng C; Li Y
Pharmacol Res; 2023 Jan; 187():106587. PubMed ID: 36460279
[TBL] [Abstract][Full Text] [Related]
26. Cucurbitacins and the Immune System: Update in Research on Anti- inflammatory, Antioxidant, and Immunomodulatory Mechanisms.
Silvestre GFG; de Lucena RP; da Silva Alves H
Curr Med Chem; 2022; 29(21):3774-3789. PubMed ID: 34994307
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Ahmed MS; Halaweish FT
J Enzyme Inhib Med Chem; 2014 Apr; 29(2):162-7. PubMed ID: 23368732
[TBL] [Abstract][Full Text] [Related]
28. Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line.
Lang KL; Silva IT; Machado VR; Zimmermann LA; Caro MS; Simões CM; Schenkel EP; Durán FJ; Bernardes LS; de Melo EB
J Mol Graph Model; 2014 Mar; 48():70-9. PubMed ID: 24378396
[TBL] [Abstract][Full Text] [Related]
29. ANTITUMOR AND APOPTOTIC EFFECTS OF CUCURBITACIN A IN A-549 LUNG CARCINOMA CELLS IS MEDIATED VIA G2/M CELL CYCLE ARREST AND M-TOR/PI3K/AKT SIGNALLING PATHWAY.
Wang WD; Liu Y; Su Y; Xiong XZ; Shang D; Xu JJ; Liu HJ
Afr J Tradit Complement Altern Med; 2017; 14(2):75-82. PubMed ID: 28573224
[TBL] [Abstract][Full Text] [Related]
30. Chemical modification produces species-specific changes in cucurbitacin antifeedant effect.
Lang KL; Deagosto E; Zimmermann LA; Machado VR; Campos Bernardes LS; Schenkel EP; Duran FJ; Palermo J; Rossini C
J Agric Food Chem; 2013 Jun; 61(23):5534-9. PubMed ID: 23646892
[TBL] [Abstract][Full Text] [Related]
31. Actin-aggregating cucurbitacins from Physocarpus capitatus.
Maloney KN; Fujita M; Eggert US; Schroeder FC; Field CM; Mitchison TJ; Clardy J
J Nat Prod; 2008 Nov; 71(11):1927-9. PubMed ID: 18959442
[TBL] [Abstract][Full Text] [Related]
32. Use of cucurbitacins for lung cancer research and therapy.
Liu M; Yan Q; Peng B; Cai Y; Zeng S; Xu Z; Yan Y; Gong Z
Cancer Chemother Pharmacol; 2021 Jul; 88(1):1-14. PubMed ID: 33825035
[TBL] [Abstract][Full Text] [Related]
33. Cucurbitacin covalent bonding to cysteine thiols: the filamentous-actin severing protein Cofilin1 as an exemplary target.
Gabrielsen M; Schuldt M; Munro J; Borucka D; Cameron J; Baugh M; Mleczak A; Lilla S; Morrice N; Olson MF
Cell Commun Signal; 2013 Aug; 11():58. PubMed ID: 23945128
[TBL] [Abstract][Full Text] [Related]
34. Identification of seven undescribed cucurbitacins in Cucumis sativus (cucumber) and their cytotoxic activity.
Qing Z; Shi Y; Han L; Li P; Zha Z; Liu C; Liu X; Huang P; Liu Y; Tang Q; Zeng K; Zeng J; Zhou Y
Phytochemistry; 2022 May; 197():113123. PubMed ID: 35182783
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo anticancer properties of cucurbitacin isolated from Cayaponia racemosa.
Militão GC; Dantas IN; Ferreira PM; Alves AP; Chaves DC; Monte FJ; Pessoa C; Odorico de Moraes M; Costa-Lotufo LV
Pharm Biol; 2012 Dec; 50(12):1479-87. PubMed ID: 22950710
[TBL] [Abstract][Full Text] [Related]
36. Cucurbitacin-I induces hypertrophy in H9c2 cardiomyoblasts through activation of autophagy via MEK/ERK1/2 signaling pathway.
Wu Y; Chen H; Li R; Wang X; Li H; Xin J; Liu Z; Wu S; Jiang W; Zhu L
Toxicol Lett; 2016 Dec; 264():87-98. PubMed ID: 27836799
[TBL] [Abstract][Full Text] [Related]
37. Liver cancer antiproliferative activity of a new nor-cucurbitacin from Mareya micrantha Müll. Arg.
Toussaint-Douhoré GY; Soro Y; Ouédraogo N; Vaca-Garcia C; Koffi-Attioua B; Carraz M
Fitoterapia; 2023 Apr; 166():105471. PubMed ID: 36918040
[TBL] [Abstract][Full Text] [Related]
38. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I.
Graness A; Poli V; Goppelt-Struebe M
Biochem Pharmacol; 2006 Jun; 72(1):32-41. PubMed ID: 16707113
[TBL] [Abstract][Full Text] [Related]
39. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
40. Critical enzymes for biosynthesis of cucurbitacin derivatives in watermelon and their biological significance.
Kim YC; Choi D; Cha A; Lee YG; Baek NI; Rimal S; Sang J; Lee Y; Lee S
Commun Biol; 2020 Aug; 3(1):444. PubMed ID: 32796947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
